Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q4779956> ?p ?o }
Showing triples 1 to 30 of
30
with 100 triples per page.
- Q4779956 subject Q15252755.
- Q4779956 subject Q5920511.
- Q4779956 subject Q6442932.
- Q4779956 subject Q8297717.
- Q4779956 subject Q8419336.
- Q4779956 subject Q8791920.
- Q4779956 abstract "Aplaviroc (INN, codenamed AK602 and GSK-873140) is a CCR5 entry inhibitor that belongs to a class of 2,5-diketopiperazines developed for the treatment of HIV infection. It was developed by GlaxoSmithKline.In October 2005, all studies of aplaviroc were discontinued due to liver toxicity concerns. Some authors have claimed that evidence of poor efficacy may have contributed to termination of the drug's development; the ASCENT study, one of the discontinued trials, showed aplaviroc to be under-effective in many patients even at high concentrations.".
- Q4779956 thumbnail Aplaviroc_structure.svg?width=300.
- Q4779956 wikiPageWikiLink Q1345259.
- Q4779956 wikiPageWikiLink Q1349821.
- Q4779956 wikiPageWikiLink Q14865176.
- Q4779956 wikiPageWikiLink Q15252755.
- Q4779956 wikiPageWikiLink Q15787.
- Q4779956 wikiPageWikiLink Q212322.
- Q4779956 wikiPageWikiLink Q418153.
- Q4779956 wikiPageWikiLink Q5009692.
- Q4779956 wikiPageWikiLink Q5920511.
- Q4779956 wikiPageWikiLink Q6442932.
- Q4779956 wikiPageWikiLink Q824258.
- Q4779956 wikiPageWikiLink Q8297717.
- Q4779956 wikiPageWikiLink Q8419336.
- Q4779956 wikiPageWikiLink Q8791920.
- Q4779956 type ChemicalSubstance.
- Q4779956 type Drug.
- Q4779956 type ChemicalObject.
- Q4779956 type Thing.
- Q4779956 type Q8386.
- Q4779956 comment "Aplaviroc (INN, codenamed AK602 and GSK-873140) is a CCR5 entry inhibitor that belongs to a class of 2,5-diketopiperazines developed for the treatment of HIV infection. It was developed by GlaxoSmithKline.In October 2005, all studies of aplaviroc were discontinued due to liver toxicity concerns.".
- Q4779956 label "Aplaviroc".
- Q4779956 depiction Aplaviroc_structure.svg.